Orient Europharma Co

Orient Europharma Co Equity

The The Equity of Orient Europharma Co (4120.TWO) as of Nov 22, 2026 is 6.29 B TWD. In the previous year, The Equity was 5.16 B TWD — a change of 21.75% (higher).

Equity

6.29 BTWD

YoY

21.75%

Last updated:

In 2025, Orient Europharma Co's equity was 6.29 B TWD, a 21.75% increase from the 5.16 B TWD equity in the previous year.

The Orient Europharma Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
3.28 B TWD
Jan 1, 2019
3.19 B TWD
Jan 1, 2020
3.21 B TWD
Jan 1, 2021
2.94 B TWD
Jan 1, 2022
2.93 B TWD
Jan 1, 2023
3.51 B TWD
Jan 1, 2024
5.16 B TWD
Jan 1, 2025
6.29 B TWD
The Orient Europharma Co Equity history
YEAREquityYoY
6.29 BTWD+21.75%
5.16 BTWD+46.94%
3.51 BTWD+19.99%
2.93 BTWD-0.43%
2.94 BTWD-8.32%
3.21 BTWD+0.44%
3.19 BTWD-2.69%
3.28 BTWD+0.46%
3.27 BTWD+3.92%
3.14 BTWD+8.76%
2.89 BTWD+2.11%
2.83 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Europharma Co Stock analysis

What does Orient Europharma Co do? Orient Europharma Co Ltd manufactures and trades western medicine, health food, and cosmetics. The company operates in the nutritious healthcare products and medical cosmetic products segment, offering infant milk powders, nutritious products, and functional healthcare products. It also provides dermatological preparations, medical hair care series, organic skin care series, and medical make-up products. In the western drugs segment, the company supplies products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases, and asthma. The company's primary customers include consumers seeking healthcare solutions and beauty products. Its products are sold under the company's own brand, targeting health-conscious individuals and those requiring medical-grade skincare and pharmaceuticals. The firm's segments focus on delivering specialized products for specific health conditions and cosmetic needs. Orient Europharma Co Ltd generates revenue through the sale of its manufactured and traded products across multiple segments. The nutritious healthcare products segment contributes to sales of infant milk powders and functional healthcare items, while the medical cosmetic products segment drives sales of dermatological and organic skincare lines. The western drugs segment supports revenue through pharmaceuticals for chronic and acute medical conditions. Orient Europharma Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Orient Europharma Co's Equity

Orient Europharma Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Orient Europharma Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Orient Europharma Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Orient Europharma Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Orient Europharma Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Orient Europharma Co stock

The Equity of Orient Europharma Co is 6.29 B TWD in 2025.

The Equity of Orient Europharma Co changed from 5.16 B TWD to 6.29 B TWD, representing a 21.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Orient Europharma Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Orient Europharma Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Orient Europharma Co

All Key Metrics — Orient Europharma Co